YUPELRI

Peak

revefenacin

NDAINHALATIONSOLUTION

Approved

Nov 2018

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

Cholinergic Antagonists

Pharmacologic Class:

Anticholinergic

Loss of Exclusivity

LOE Date

Oct 23, 2039

165 months away

Patent Expiry

Oct 23, 2039

Patent Records (5)

Patent #	Expiry	Type	Use Code
7288657	Oct 31, 2028	Substance	—
11008289	Jul 14, 2030		U-2440
11691948	Jul 14, 2030	Product	—
11858898	Jul 14, 2030	SubstanceProduct	U-2440
10550081	Jul 14, 2030	Substance	—

Company

China - Shanghai

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers